Conditions: Endometrial Serous Adenocarcinoma; Stage I Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage III Uterine Corpus Cancer; Stage IV Uterine Corpus Cancer Interventions: Other: Diagnostic Laboratory Biomarker Analysis; Other: Immunohistochemistry Staining Method; Other: Medical Chart Review; Genetic: Microarray Analysis; Other: Study of Socioeconomic and Demographic Variables; Genetic: Western Blotting Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI) Not yet recruiting
Conditions: Healthy Subject; Hereditary Pancreatic Carcinoma; Pancreatic Adenocarcinoma; Pancreatic Intraductal Papillary Mucinous Neoplasm Interventions: Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging; Drug: Ferumoxytol Sponsors: OHSU Knight Cancer Institute; National Cancer Institute (NCI); National Institute for Biomedical Imaging and Bioengineering (NIBIB) Recruiting
Condition: Thyroid Cancer, Papillary Intervention: Procedure: prophylactic central lymph node dissection Sponsor: Seoul National University Hospital Recruiting
Condition: Carcinoma, Papillary, Follicular Intervention: Device: Using Neuromonitoring to find EBSLN Sponsor: Seoul National University Hospital Recruiting
Conditions: Acinar Cell Carcinoma; Ampulla of Vater Adenocarcinoma; Cholangiocarcinoma; Duodenal Adenocarcinoma; Pancreatic Adenocarcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Intraductal Papillary Mucinous Neoplasm, Pancreatobiliary-Type; Periampullary Adenocarcinoma Interventions: Procedure: Pancreatectomy; Other: Lavage Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University Recruiting
Condition: Papillary Thyroid Cancer Intervention: Drug: Imatinib Oral Tablet Sponsors: AHS Cancer Control Alberta; Alberta Cancer Foundation Recruiting
Condition: Thyroid Cancer Stage I Intervention: Sponsors: University Health Network, Toronto; Ontario Ministry of Health and Long Term Care; Canadian Cancer Society Research Institute (CCSRI) Recruiting
Conditions: HLRCC; Sporadic Papillary Renal Cell Cancer Interventions: Drug: Bevacizumab; Drug: Erlotinib Sponsor: National Cancer Institute (NCI) Recruiting
Conditions: Stage I Papillary Thyroid Cancer; Stage II Papillary Thyroid Cancer; Stage III Papillary Thyroid Cancer Interventions: Procedure: Thyroidectomy; Procedure: Central lymph node dissection; Other: Quality-of-life assessment Sponsors: University of Wisconsin, Madison; National Cancer Institute (NCI) Recruiting
Conditions: Papillary Thyroid Cancer; Lymph Node Metastases Interventions: Drug: IV adminstration of EMI-137; Device: Multispectral Fluorescence Reflectance Imaging; Device: Spectroscopy Sponsors: University Medical Center Groningen; Erasmus Medical Center Recruiting
Conditions: Thyroid Cancer; Papillary Thyroid Carcinoma; Thyroidectomy; Endoscopy Interventions: Device: used of the Pressure adjustable foot-control method; Device: direct exhaust Sponsor: Bo Wang,MD Recruiting
Conditions: Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma; Unresectable Renal Cell Carcinoma Interventions: Drug: Cabozantinib; Drug: Cabozantinib S-malate; Drug: Crizotinib; Drug: Savolitinib; Drug: Sunitinib; Drug: Sunitinib Malate Sponsors: National Cancer Institute (NCI); Canadian Cancer Trials Group Recruiting